Triumeq (abacavir, dolutegravir, and lamivudine) Tablets, For Oral Use

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) April 2016 ADVERSE REACTIONS Clinical Trials Experience Week 144 safety and efficacy data from Phase III study ING114467...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts